You are here

Eli Lilly

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Mylan, Biocon copy inches closer to challenging Sanofi's long-suffering Lantus

Fierce Pharma

Boehringer Ingelheim

Flag link:

Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug

Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug

Fierce Biotech

Alzheimer's disease

Flag link:

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design

Xtalks

clinical trials

Multiple Myeloma

adaptive trial design

Flag link:

Eli Lilly's former drug yields Phase 2 win for Vanda Pharma

Eli Lilly's former drug yields Phase 2 win for Vanda Pharma

Biopharma Dive

Vanda Pharmaceuticals

clinical trials

Flag link:

Rising fear among Asians leads Eli Lilly to rethink employee groups

Rising fear among Asians leads Eli Lilly to rethink employee groups

Indianpolis Business Journal

Flag link:

Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials

Lilly CMO Robert Brown to lead Brickell Bio as it eyes phase 3 dermatology trials

Fierce Biotech

Flag link:

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years

BioSpace

Ariad Pharmaceuticals

Boehringer Ingelheim

Bristol-Myers Squibb

Puma Biotechnology

Flag link:

Eli Lilly Could Sell Some Older China Assets for up to $300 Million

Eli Lilly Could Sell Some Older China Assets for up to $300 Million

BioSpace

Flag link:

After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer

After historic win, Lilly partner Chi-Med’s Elunate flops in lung cancer

Fierce Pharma

non-small cell lung cancer

Flag link:

7 drugs that raised eyebrows in Q3

7 drugs that raised eyebrows in Q3

Biopharma Dive

Clovis Oncology

Flag link:

Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache

Lilly's third-to-market Emgality nets FDA 'breakthrough' in cluster headache

Fierce Pharma

cluster headaches

breakthrough therapies

Flag link:

Eli Lilly backs away from Bace but not from novel Alzheimer’s targets

Eli Lilly backs away from Bace but not from novel Alzheimer’s targets

EP Vantage

drug development

Alzheimer's disease

BACE inhibitors

Flag link:

Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan

Biotech Eli Lilly files for FDA approval of migraine drug lasmiditan

Fierce Biotech

Flag link:

Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardiovascular Health

Viagra and Cialis: PDE-5 Inhibitors May Have Broader Applications in Cancer, Neurology and Cardiovascular Health

BioSpace

erectile dysfunction

drug repurposing

Flag link:

Fresh from Eli Lilly deal, NextCure bags $93M for clinical push

Fresh from Eli Lilly deal, NextCure bags $93M for clinical push

Fierce Biotech

Flag link:

Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s

Eli Lilly sweeps the rest of the BACE work out of the pipeline following their latest major setback on Alzheimer’s

Endpoints

Alzheimer's disease

BACE inhibitors

Flag link:

Despite Trulicity success, Lilly can't escape diabetes concerns

Despite Trulicity success, Lilly can't escape diabetes concerns

Biopharma Dive

Flag link:

Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs

Eli Lilly Commits $40M to NextCure in Hunt for New Cancer Drugs

Xconomy

cancer immunotherapy

drug development

Flag link:

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

Eli Lilly touts MACE win for diabetes blockbuster Trulicity — a 'nice positive'

Endpoints

Flag link:

Early November Brings More Quarterly Reports

Early November Brings More Quarterly Reports

BioSpace

Flag link:

Pages